Trials / Completed
CompletedNCT01485640
Lurasidone Extended Use Study
A Long-term, Multicenter, Open-Label, Flexible Dose Continuation Study in Subjects Who Have Completed a Prior Lurasidone Study
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 162 (actual)
- Sponsor
- Sumitomo Pharma America, Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is an open-label continuation study designed to monitor the safety, tolerability and effectiveness of lurasidone in subjects who have completed participation in a lurasidone extension study (NCT00868959 and NCT01566162) and who may benefit from continued treatment with lurasidone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lurasidone | Lurasidone flexibly dosed; doses of 20, 40, 60 or 80 mg/day will be taken orally with food |
Timeline
- Start date
- 2011-06-01
- Primary completion
- 2014-02-01
- Completion
- 2014-02-01
- First posted
- 2011-12-05
- Last updated
- 2016-11-04
- Results posted
- 2015-03-11
Locations
46 sites across 12 countries: Canada, Colombia, Czechia, France, India, Lithuania, Romania, Russia, Serbia, Slovakia, South Africa, Ukraine
Source: ClinicalTrials.gov record NCT01485640. Inclusion in this directory is not an endorsement.